Luc Truyen, MD, PhD

Articles

Luc Truyen, MD, PhD: Long-Term Results of Ponesimod in Phase 2b Study

September 18, 2020

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed the results of a phase 2 core and extension study of ponesimod in patients with relapsing-remitting multiple sclerosis.